// startup autopsy
Caldan Therapeutics
Targeted therapies that couldn't target enough capital to survive.
marketfitSilent Shutdown
Quiet closure with no public announcement · Fatal mistake: Failed to reach clinical proof-of-concept milestones necessary to attract Series B investment before seed capital was exhausted.
Key Events Timeline
FOUNDING
Caldan Therapeutics founded in the UK to develop targeted therapeutic compounds.
FUNDING
Early-stage funding secured to initiate preclinical research programs.
FUNDING
Final funding round closed; total raised reached ~$6.86M as the company pursued IND-enabling studies.
REGULATORY ACTION
Clinical development program stalled as preclinical data failed to fully support advancement; investors declined follow-on.
SHUTDOWN
Caldan Therapeutics silently wound down operations after exhausting its remaining capital without a clinical readout.